The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stent cells or growth factors.

The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stent cells or growth factors.

The invention provides composite materials that form a biocompatible and bioresorbable settable ceramic-forming composition, and that possesses high strength when set and other desirable mechanical properties. The composite materials may include additive materials that provide beneficial advantages in the handling and physical properties of the material. When a hydrated precursor, the composite material is capable of being injected through cannulas for placement in treatment sites. The composite material provided desirable handling properties and sets in a clinically relevant time period.

The invention provides composite materials that form a biocompatible and bioresorbable settable ceramic-forming composition, and that possesses high strength when set and other desirable mechanical properties. The composite materials may include additive materials that provide beneficial advantages in the handling and physical properties of the material. When a hydrated precursor, the composite material is capable of being injected through cannulas for placement in treatment sites. The composite material provided desirable handling properties and sets in a clinically relevant time period.

The invention provides composite materials that form a biocompatible and bioresorbable settable ceramic-forming composition, and that possesses high strength when set and other desirable mechanical properties. The composite materials may include additive materials that provide beneficial advantages in the handling and physical properties of the material. When a hydrated precursor, the composite material is capable of being injected through cannulas for placement in treatment sites. The composite material provided desirable handling properties and sets in a clinically relevant time period.

A functionally gradient material for guided periodontal hard and soft tissue regeneration includes a 3D printed scaffold layer and an electrospun fibrous membrane layer. The content of hydroxyapatite in the 3D printed scaffold layer is higher than the content of hydroxyapatite in the electrospun fibrous membrane layer. The pore size of the 3D printed scaffold layer is larger than the pore size of the electrospun fibrous membrane layer. The pore size of the 3D printed scaffold layer is 100-1000 μm, and the fiber diameter of the electrospun fibrous membrane layer is 300-5000 nm. The electrospun fibrous membrane layer is in a random distribution or an oriented arrangement or has a mesh structure. The thickness of the electrospun fibrous membrane layer is 0.08-1 mm.

A functionally gradient material for guided periodontal hard and soft tissue regeneration includes a 3D printed scaffold layer and an electrospun fibrous membrane layer. The content of hydroxyapatite in the 3D printed scaffold layer is higher than the content of hydroxyapatite in the electrospun fibrous membrane layer. The pore size of the 3D printed scaffold layer is larger than the pore size of the electrospun fibrous membrane layer. The pore size of the 3D printed scaffold layer is 100-1000 μm, and the fiber diameter of the electrospun fibrous membrane layer is 300-5000 nm. The electrospun fibrous membrane layer is in a random distribution or an oriented arrangement or has a mesh structure. The thickness of the electrospun fibrous membrane layer is 0.08-1 mm.

This disclosure relates to methods of mineralizing cell-laden matrices. Disclosed herein are cell-laden matrix compositions. Also disclosed herein are methods of selectively mineralizing a cell-laden matrix. Methods of culturing biomimetic bone tissue are disclosed herein. Also disclosed herein are kits containing compositions disclosed herein or portions thereof.

This disclosure relates to methods of mineralizing cell-laden matrices. Disclosed herein are cell-laden matrix compositions. Also disclosed herein are methods of selectively mineralizing a cell-laden matrix. Methods of culturing biomimetic bone tissue are disclosed herein. Also disclosed herein are kits containing compositions disclosed herein or portions thereof.

The present invention refers to a method of manufacturing an implantable construct comprising chondrogenically differentiated cells and one or more polycaprolactone (PCL) microcarriers, an implantable construct produced using said method, and uses of the implantable construct. The present invention also refers to a method of manufacturing an implantable construct comprising mesenchymal stromal cells and one or more polycaprolactone (PCL) microcarriers, an implantable construct produced using said method, and uses of the implantable construct. The present invention further refers to a method of treating a disease or disorder associated with cartilage and/or bone defect, the method comprises administering one or more cell-free polycaprolactone (PCL) microcarriers in a patient suffering from the disease or disorder.